adj.

抗パーキンソン病の

n.

抗パーキンソン病薬

関: antiparkinson agent、antiparkinson drug、antiparkinsonian agent、antiparkinsonian drug

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/04/19 20:09:34」(JST)

wiki en

An antiparkinson medication is a type of drug which is intended to treat and relieve the symptoms of Parkinson's disease. Most of these agents act by either increasing dopamine activity or reducing acetylcholine activity in the central nervous system.

Parkinson's disease

Parkinson's disease is a motor system disorder of the nervous system. It is outlined as a progressive disorder that affects movement and results in the loss of dopamine-producing brain cells, causing tremor in the hands, arms, legs, jaw, and face and/or rigidity or stiffness of the limbs and trunk.^[1] The primary symptoms are muscular rigidity, slowness of movement, a resting tremor, and postural instability.^[2] Parkinson’s disease is caused by degeneration of the nigrostriatal system, which is the dopamine-secreting neurons of the substantia nigra that send axons to the basal ganglia.^[3] The basal ganglia controls the automatic, habitual responses performed by the human body.

This picture shows the Substantia nigra, the part of the brain that is affected in Parkinson's disease.

It is difficult to diagnose Parkinson’s disease, as there is no specific test for it. Doctors usually perform other tests in order to rule out other conditions.^[4] Often seen in the dopaminergic neurons in the brains of patients who have Parkinson’s disease, are Lewy bodies, which are abnormal circular structures found within the cytoplasm. Lewy bodies have a dense protein core, surrounded by a halo of radiating fibers.^[5] Mutations on chromosome 4 can cause Parkinson’s disease. This gene produces a protein known as a-synuclein. This protein which is normally found in the presynaptic terminals and is thought to be involved in synaptic transmission in dopaminergic neurons. The mutation produces what it known as a toxic gain of function because it produces a protein that results in effects that are toxic to the cell. Parkinson’s disease can also be caused by a mutation on chromosome 6. This gene has been named parkin. This mutation causes a loss of function, which makes it a recessive disorder.^[6]

Common medication

This picture shows the dopamine pathways in the brain. The goal of antiparkinson agents is to restore these pathways to full function.

The goal of the most common Antiparkinson drugs is to either replace the dopamine levels in the brain, or mimic the actions of dopamine. The main categories of Antiparknison drugs are anticholinergic drugs and dopaminergic drugs. Anticholinergic drugs block the action of acetylcholine, compensating for the low levels of dopamine. As stated before, dopaminergic drugs aim to replace dopamine or inhibit the degradation of dopamine in the brain.^[7]

L-DOPA

Once a preliminary diagnosis is made, carbidopa-levodopa can be given as an antiparkinson medication. If this medication shows improvement, doctors will likely confirm their diagnosis. This standard treatment for Parkinson’s disease is referred to as L-DOPA, the precursor of dopamine. L-DOPA causes the person’s remaining dopaminergic neurons to produce and secrete more dopamine, counteracting the effects of Parkinson’s disease. However, eventually the nigrostriatal dopaminergic neurons in the brain drop to a low enough count where the symptoms of Parkinson’s disease become worse. This is due to the short half-life of L-DOPA in the body; typically 1.5–2 hours.^[8] L-DOPA also activates DA neurons in the mesolimbic/mesocortical system and produces side effects such as hallucinations and delusions.^[9]

Deprenyl

A medicine that can be given with L-DOPA, or separately, is deprenyl. Deprenyl inhibits the activity of the enzyme MAO-B, which then will slow the progression of Parkinson’s disease. Deprenyl, however, does not completely stop the degeneration of dopaminergic neurons.^[10] Deprenyl delays the time before other antiparkinson drugs, like L-DOPA, need to be used.^[11]

Tyrosine hydroxylase

Tyrosine hydroxylase catalyzes the formation of L-DOPA, the rate-limiting step in the biosynthesis of dopamine.^[12] In other words, it is a precursor to neurotransmitters and increases plasma neurotransmitter levels of dopamine and norepinephrine.^[13] This medication should not be used when taking L-DOPA, as L-DOPA interferes with the absorption of Tyrosine.^[14]

Apomorphine

Apomorphine has also been used to treat Parkinson's disease. It is referred to as a dopamine receptor agonist. However, it does cause severe side effects when used on its own.^[15]

Anticholinergic drugs

Anticholinergic drugs include benzhexol and orphenadrine. These drugs reduce the effect of acetylcholine in the brain by antagonizing cholinergic receptors. This helps restore the acetylcholine/dopamine balance within the brain. Again with these treatments, about 70% of patients taking anticholinergics develop serious side effects, including hallucinations, dyskinetic movements, vision effects, difficulty swallowing, dry mouth and urine retention.^[16]

mGluR4

N-phenyl-7-(hydroxylimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) is now being studied as a selective allosteric potentiator of mGluR4. Metabotropic glutamate receptor 4 (mGluR4) is a potential drug target for Parkinson's disease. PHCCC selectively potentiated agonist-induced mGluR4 activity in cells expressing this receptor and did not itself act as an agonist. PHCCC also potentiated the effect of L-(+)-2-amino-4-phosphonobutyric acid in inhibiting transmission at the striatopallidal synapse. This is significant due to the striatopallidal synapse being proposed as a target for Parkinson's disease treatment. This can hopefully restore balance in the basal ganglia motor circuit.^[17]

Research

Recent research for alleviating the symptoms of Parkinson’s disease involves stereotaxic procedures. These procedures are typically done when patients no longer respond to antiparkinson drugs. These procedures include transplantation of fetal tissue in an attempt to reestablish the secretion of dopamine in the neostriatum. Researchers have also attempted strategies of gene therapy. A genetically modified virus was inserted into the subthalamic nucleus of patients with Parkinson’s disease. This virus delivered a gene for GAD, which is the enzyme responsible for the biosynthesis of the major inhibitory neurotransmitter, GABA. In the study, GAD turned some of the excitatory glutamate-producing neurons in the sub-thalamic nucleus into inhibitory, GABA-producing neurons, improving the symptoms of Parkinson’s disease.^[18]

Examples

- Dopaminergic precursors:

(Preferred over other medications to prevent undesirable sympathomimetic side effects)

- - Phenylalanine
  - Tyrosine
  - L-DOPA
- Selective monoamine oxidase B inhibitors

(To prevent the metabolism of dopamine by MAO_B and hence increase its brain levels)

- - Selegiline
  - Rasagiline
- COMT inhibitors

(Preventing the metabolism of dopamine by COMT and hence increase its brain levels)

- - Entacapone
  - Tolcapone
- Dopamine receptor agonists

(Directly increase the activity of the dopamine system)

- - Apomorphine
  - Bromocriptine
  - Pramipexole
  - Ropinirole
  - Rotigotine
Anticholinergics - Antimuscarinics (e.g., Benzatropine): to prevent hyperkinesia.
- Diphenhydramine
- Dimenhydrinate
- Scopolamine
- Benztropine

References

^ NINDS. "NINDS Parkinson's Disease Information Page." Parkinson's Disease Information Page: National Institute of Neurological Disorders and Stroke (NINDS). National Institute of Neurological Disorders and Stroke, 12 Mar. 2014. Web. 12 Mar. 2014.
^ Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.
^ Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.
^ Mayo Clinic Staff. "Parkinson's Disease." Diagnosis at Mayo Clinic. Mayo Foundation for Medical Education and Research, 2014. Web. 12 Mar. 2014.
^ Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.
^ Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.
^ Parkinson's UK. "Anticholinergics". Retrieved 30 April 2014.
^ NIH DailyMed. "Sinemet". Retrieved 21 August 2014.
^ Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.
^ Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.
^ Tetrud, JW; JW Langston (4 August 1989). "The effect of deprenyl (selegiline) on the natural history of Parkinson's disease". Science 245 (4917): 519–522. doi:10.1126/science.2502843. PMID 2502843.
^ Haavik, J; Toska, K. (June 1998). "Tyrosine Hydroxylase and Parkinson's". Mol. Neurobiol. 16 (3): 285–309. doi:10.1007/BF02741387. PMID 9626667.
^ Rasmussen, DD; Ishizuka, B; Quigley, ME; Yen, SS (1983). "Effects of tyrosine and tryptophan ingestion on plasma catecholamine and 3,4-dihydroxyphenylacetic acid concentrations". J. Clin. Endocrinol. Metab 57 (4): 760–3. doi:10.1210/jcem-57-4-760. PMID 6885965.
^ University of Maryland Medical Center. "Tyrosine". Retrieved 30 April 2014.
^ Donovan, Stephen. "Parkinson's Disease Treatment". Retrieved 16 April 2014.
^ Donovan, Stephen. "Parkinson's Disease Treatment". Retrieved 16 April 2014.
^ Marino, Michael (11 November 2003). "Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment". PNAS 100 (23): 13668–13673. doi:10.1073/pnas.1835724100. PMC: 263871. PMID 14593202.
^ Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 抗精神病薬、ベンゾジアゼピン、リチウム、および電気けいれん療法の催奇形性および出生後のリスク teratogenic and postnatal risks of antipsychotics benzodiazepines lithium and electroconvulsive therapy
2. パーキンソン病の薬理学的治療 pharmacologic treatment of parkinson disease
3. 神経疾患を有する手術患者の周術期ケア perioperative care of the surgical patient with neurologic disease
4. 統合失調症におけるうつ病 depression in schizophrenia
5. 統合失調症に対する薬物療法：副作用マネージメント pharmacotherapy for schizophrenia side effect management

English Journal

Probing the interaction of a coumarin-di(2-picolyl)amine hybrid drug-like molecular entity with human serum albumin: Multiple spectroscopic and molecular modeling techniques.

Khan S, Zafar A, Naseem I.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2019 Dec;223()117330.
HSA is an important plasma protein responsible for transport of drug molecules. Coumarin derivatives play critical role as anticancer, antidiabetic and antiparkinson agents. In our lab we have synthesized coumarin-based pharmacophore, di(2-picolyl)amine-3(bromoacetyl) coumarin (ligand-L) endowed wit
PMID 31280128

Prevalence and incidence of Parkinson's disease and drug-induced parkinsonism in Korea.

Han S, Kim S, Kim H, Shin HW, Na KS, Suh HS.
BMC public health. 2019 Oct;19(1)1328.
Parkinson's disease (PD) and drug-induced parkinsonism (DIP) are the major diseases of parkinsonism. To better understand parkinsonism, we aimed to assess the prevalence and incidence of PD and DIP in Korea from 2012 to 2015. We used the Health Insurance Review and Assessment Service database, which
PMID 31640652
PMID 29763128

Japanese Journal

脳出血後の療養中に発症し診療中のMeige症候群の男性例

日本農村医学会雑誌 64(4), 705-710, 2015
NAID 130005118926

消化器症状と睡眠および精神症状との関連性について : 精神科外来患者を対象とした研究(睡眠医学が心身医学に寄与できること,2013年,第54回日本心身医学会総会ならびに学術講演会(横浜))

心身医学 54(3), 242-250, 2014-03-01
NAID 110009806436

パーキンソン病の総合的治療方針

The Japanese Journal of Rehabilitation Medicine 51(11), 700-704, 2014
NAID 130004705541

「抗パーキンソン病薬」

　　[★]

英: antiparkinsonian drug、antiparkinsonian agent、antiparkinsonian、antiparkinson drug、antiparkinson agent
関: 抗パーキンソン病、抗パーキンソン剤

「antiparkinson drug」

　　[★]

抗パーキンソン病薬

関: antiparkinson agent、antiparkinsonian、antiparkinsonian agent、antiparkinsonian drug

「antiparkinson agent」

　　[★]

抗パーキンソン病薬

関: antiparkinson drug、antiparkinsonian、antiparkinsonian agent、antiparkinsonian drug

「抗パーキンソン病」

　　[★]

英: antiparkinsonian
関: 抗パーキンソン病薬

「antiparkinsonian drug」

　　[★]

抗パーキンソン病薬、抗パーキンソン剤

関: antiparkinson agent、antiparkinson drug、antiparkinsonian、antiparkinsonian agent

「antiparkinsonian agent」

　　[★]

抗パーキンソン病薬

関: antiparkinson agent、antiparkinson drug、antiparkinsonian、antiparkinsonian drug

[1] NINDS. "NINDS Parkinson's Disease Information Page." Parkinson's Disease Information Page: National Institute of Neurological Disorders and Stroke (NINDS). National Institute of Neurological Disorders and Stroke, 12 Mar. 2014. Web. 12 Mar. 2014.

[2] Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.

[3] Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.

[4] Mayo Clinic Staff. "Parkinson's Disease." Diagnosis at Mayo Clinic. Mayo Foundation for Medical Education and Research, 2014. Web. 12 Mar. 2014.

[5] Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.

[6] Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.

[7] Parkinson's UK. "Anticholinergics". Retrieved 30 April 2014.

[8] NIH DailyMed. "Sinemet". Retrieved 21 August 2014.

[9] Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.

[10] Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.

[11] Tetrud, JW; JW Langston (4 August 1989). "The effect of deprenyl (selegiline) on the natural history of Parkinson's disease". Science 245 (4917): 519–522. doi:10.1126/science.2502843. PMID 2502843.

[12] Haavik, J; Toska, K. (June 1998). "Tyrosine Hydroxylase and Parkinson's". Mol. Neurobiol. 16 (3): 285–309. doi:10.1007/BF02741387. PMID 9626667.

[13] Rasmussen, DD; Ishizuka, B; Quigley, ME; Yen, SS (1983). "Effects of tyrosine and tryptophan ingestion on plasma catecholamine and 3,4-dihydroxyphenylacetic acid concentrations". J. Clin. Endocrinol. Metab 57 (4): 760–3. doi:10.1210/jcem-57-4-760. PMID 6885965.

[14] University of Maryland Medical Center. "Tyrosine". Retrieved 30 April 2014.

[15] Donovan, Stephen. "Parkinson's Disease Treatment". Retrieved 16 April 2014.

[16] Donovan, Stephen. "Parkinson's Disease Treatment". Retrieved 16 April 2014.

[17] Marino, Michael (11 November 2003). "Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment". PNAS 100 (23): 13668–13673. doi:10.1073/pnas.1835724100. PMC: 263871. PMID 14593202.

[18] Neil Carlson. Pearson Education, Inc., ed. Psychology of Behavior (11 ed.). pp. 533–538.

リンク元	「抗パーキンソン病薬」「antiparkinson drug」「antiparkinson agent」「抗パーキンソン病」
拡張検索	「antiparkinsonian drug」「antiparkinsonian agent」

匿名

検索

案内

案内

antiparkinsonian